We partner with non-profit organizations, pharmaceutical companies and investors to strategically de-risk, advance, and grow our portfolio of discoveries.
Advent Life Sciences and Harrington have partnered to launch the Advent-Harrington Impact Fund, a global investment fund to advance breakthrough discoveries into novel treatments.
The ADDF-Harrington Scholar Award drives research efforts that seek to prevent, treat or cure Alzheimer's disease, related dementias and cognitive-decline associated with aging.
The Harrington Prize for Innovation in Medicine, awarded jointly with the American Society for Clinical Investigation, honors a physician-scientist globally for an achievement notable for innovation, creativity and potential for clinical application.
BioMotiv is a mission driven investment fund to translate transformative discoveries into novel medicines through alignment with the right investors and commercialization partners.
The Gund Harrington Scholar Award supports the translation of innovative research in retinal degenerative diseases into new therapies to improve and/or restore vision.
Morgan Stanley GIFT (Global Impact Funding Trust) Cures powered by Harrington Discovery Institute is a special interest program for philanthropists to amplify their impact by accelerating cures for diseases.
The Harrington Rare Disease Scholar Award, sponsored by Takeda Pharmaceuticals, supports researchers whose discoveries show promise for translation into novel medicines for rare diseases.
The Oxford-Harrington Rare Disease Centre combines the strengths and capabilities of University of Oxford and Harrington Discovery Institute to accelerate cures for rare diseases.
Our approach is totally synergistic with the Harrington Discovery Institute. The amount of strategic advice they bring has been invaluable.
Howard Fillit, MD
Founding Executive Director and Chief Science Officer
Alzheimer's Drug Discovery Foundation
Harrington Discovery Institute’s ability to accelerate the drug development process by ensuring that the world’s best discoveries turn into next-generation medicines and fill unmet needs made it the ideal partner.
Melanie Schnoll Begun
Managing Partner, Head of Philanthropy Management
President, Morgan Stanley Global Impact Funding Trust (GIFT)
We are delighted to have partnered with the Harrington Discovery Institute to provide translational finance that will deliver real impact to patients in addition to strong financial returns.
Advent Life Sciences
Our partnership with Harrington Discovery Institute recognizes the combined experience needed in the world-class science and drug development if we are to change the rare disease landscape in a meaningful way.
Sir John Bell
Regius Professor of Medicine
University of Oxford